BioVie Inc (BIVI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.21-9.70%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · BIVI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
BIVI — debt issuance
Dated 2026-09-11
Entry Into a Material Definitive Agreement. On September 11, 2026, BioVie Inc., a Nevada corporation (the “Company”), entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”), pursuant to which the Company may issue and sell from time to time, to or through the Agent, shares of the Company’s Class A common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $6,464,341 (the “Placement Shares”). The Pl…
Why it matters: The Phase 2 trial reported benefits in both motor and non-motor symptoms. A later trial must test whether those effects hold.
Supportive ifBioVie starts its next Parkinson's trial and reports a pre-set measure that improves versus placebo.
Worry ifBioVie reports that the next trial misses its main measure or stops the Parkinson's program.
Why it matters: BioVie is loss-making, and the inputs give no cash balance or spending rate. An update on cash and trial costs can show funding needs.
Watch forThe November 9 report gives cash, spending, and funding details, with enough cash to cover the stated trial plans.
Also watch forThe report shows a shorter cash runway, rising trial costs, or added share sales to fund the plans.
Why it matters: The Phase 2 results were from 57 patients over 12 weeks. A clear next-trial plan would show how BioVie will test them further.
Supportive ifBioVie gives a Phase 3 start window, trial size, and key measures. It also notes the role of platelet levels above 230 x 10³/µL.
Worry ifBioVie reports no Phase 3 plan, delays the trial, or drops the platelet-based patient group from its design.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$473 on $10,000 · ±4.7% | How much price usually moves either way. |
| Bad day | $996 loss on $10,000 · 10.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,752 loss on $10,000 · 57.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.